Dolutegravir Based Regimens: Congress Data

The Use of Tivicay plus Epivir for Treatment-Naiive Adults with HIV-1

The Use of Tivicay plus Epivir for Treatment-Naiive Adults with HIV-1

GEMINI-1 and GEMINI-2 Studies

Michael Aboud, VP, Global Medical Lead, Dolutegravir

The Use of Tivicay plus Epivir for Treatment-Naiive Adults with HIV-1

GEMINI-1 and GEMINI-2 Studies

Michael Aboud, VP, Global Medical Lead, Dolutegravir

X
Dovato for Treatment Naïve Patients: GEMINI-1 & GEMINI-2

Dovato for Treatment Naïve Patients: GEMINI-1 & GEMINI-2

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

Dovato for Treatment Naïve Patients: GEMINI-1 & GEMINI-2

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

X
DTG + 3TC in Virologically Suppressed, Treatment Experienced Patients: TANGO Study

DTG + 3TC in Virologically Suppressed, Treatment Experienced Patients: TANGO Study

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

DTG + 3TC in Virologically Suppressed, Treatment Experienced Patients: TANGO Study

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

X
DTG/3TC: Real-World Evidence

DTG/3TC: Real-World Evidence

An Update from CROI 2020

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

DTG/3TC: Real-World Evidence

An Update from CROI 2020

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

X
DTG: Use in Pregnancy

DTG: Use in Pregnancy

Nneka Nwokolo, Senior Global Medical Director

DTG: Use in Pregnancy

Nneka Nwokolo, Senior Global Medical Director

X
DTG: Metabolic Data Update

DTG: Metabolic Data Update

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

DTG: Metabolic Data Update

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

X
Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

Mark Underwood, Clinical Virologist and Development Investigator

Very Low Levels of Viral Replication for DTG/3TC Versus 3DR: The TANGO Study

Mark Underwood, Clinical Virologist and Development Investigator

X
TANGO Study: Metabolic Substudy

TANGO Study: Metabolic Substudy

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

TANGO Study: Metabolic Substudy

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

X
DTG+3TC: GEMINI 144-Week Data

DTG+3TC: GEMINI 144-Week Data

An Update from HIV GLASGOW 2020

Nneka Nwokolo, Senior Global Medical Director

DTG+3TC: GEMINI 144-Week Data

An Update from HIV GLASGOW 2020

Nneka Nwokolo, Senior Global Medical Director

X
DTG+3TC: TANGO 96-Week Data

DTG+3TC: TANGO 96-Week Data

An Update from HIV GLASGOW 2020

Jose Gatell, Senior Global Medical Director

DTG+3TC: TANGO 96-Week Data

An Update from HIV GLASGOW 2020

Jose Gatell, Senior Global Medical Director

X
DTG/3TC: Confirmed Virologic Withdrawals in the GEMINI-1 and -2 Studies

DTG/3TC: Confirmed Virologic Withdrawals in the GEMINI-1 and -2 Studies

Nneka Nwokolo, Senior Global Medical Director

DTG/3TC: Confirmed Virologic Withdrawals in the GEMINI-1 and -2 Studies

Nneka Nwokolo, Senior Global Medical Director

X
DTG/3TC: Barrier to Resistance

DTG/3TC: Barrier to Resistance

Jan van Lunzen, Head of Translational Medical Research

DTG/3TC: Barrier to Resistance

Jan van Lunzen, Head of Translational Medical Research

X
Post-CROI 2021 Webinar

Post-CROI 2021 Webinar

Andrew Zolopa, MD, VP, Head, North America Medical Affairs

Post-CROI 2021 Webinar

Andrew Zolopa, MD, VP, Head, North America Medical Affairs

X
GEMINI 144 Week: Efficacy and Safety

GEMINI 144 Week: Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

GEMINI 144 Week: Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

X
TANGO 96 Week: Efficacy and Safety

TANGO 96 Week: Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

TANGO 96 Week: Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

X
GEMINI 48 Week: Adherence Analysis

GEMINI 48 Week: Adherence Analysis

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

GEMINI 48 Week: Adherence Analysis

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

X
STAT 24 Week: Feasibility, Efficacy and Safety

STAT 24 Week: Feasibility, Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

STAT 24 Week: Feasibility, Efficacy and Safety

Jean Van Wyk, MBChB, Global Medical Lead, Dolutegravir

X

Connect with our Medical Experts

Find my ViiV MSL

Easily find the ViiV Medical Science Liaison (MSL) in your area.

Request a Scientific Discussion

Submit a request for additional information from a ViiV Medical Expert.

Talk to a Medical Expert

Connect now with a live ViiV Medical Expert.

Contact Us

Chat Live

Get immediate assistance from a ViiV Healthcare Professional.

Call 1-888-226-8434

Weekdays from 8 AM to 6 PM ET
(5 AM – 3 PM PT)

Report an Adverse Event

To report SUSPECTED ADVERSE REACTIONS, contact ViiV Healthcare at 1-877-844-8872 or FDA at 1-800-332-1088 or www.fda.gov/medwatch